References

medsovet

Медицинский Совет

Meditsinskiy sovet = Medical Council

2079-701X2658-5790

REMEDIUM GROUP Ltd.

10.21518/ms2023-303

medsovet-7802

Research Article

КОМОРБИДНЫЙ ПАЦИЕНТ

COMORBID PATIENT

Метаболический синдром: перспективы использования ангиопоэтин-подобных белков 3-го и 4-го типа для диагностики метаболических нарушений

Metabolic syndrome: prospects for the use of angiopoetin-like proteins type 3 and 4 for the diagnosis of metabolic disorders

https://orcid.org/0000-0002-4500-7172

Александров

В. А.

Aleksandrov

V. A.

Александров Владислав Андреевич ассистент кафедры госпитальной терапии, ВГМУ; младший научный сотрудник, НИИ клинической и экспериментальной ревматологии имени А.Б. Зборовского;

400131, Волгоград, площадь Павших Борцов, д. 1; 400138, Волгоград, ул. им. Землячки, д. 76

Vladislav A. Aleksandrov Assistant of the Department of Hospital Therapy, Volgograd SMU; Junior Researcher, RICER named after А.B. Zborovsky.

1, Pavshikh Bortsov Square, Volgograd, 400131; 76, Zemlyachkа St., Volgograd, 400138

imlab@mail.ru

Волгоградский государственный медицинский университет; Научно-исследовательский институт клинической и экспериментальной ревматологии имени А.Б. ЗборовскогоРоссияVolgograd State Medical University; Research Institute of Clinical and Experimental Rheumatology named after А.B. ZborovskyRussian Federation

2023

21102023

0166875

2023

Александров В.А.

Aleksandrov V.A.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://www.med-sovet.pro/jour/article/view/7802

Метаболический синдром (МС) является одной из основных проблем глобального общественного здравоохранения. Общепризнанными и наиболее важными компонентами МС являются абдоминальный тип ожирения, артериальная гипертензия, нарушения углеводного обмена и дислипидемия. Важным регулятором функций жировой ткани признана ангиопоэтин-подобная система, включающая 8 известных к настоящему времени типов ангиопоэтин-подобных белков. Наиболее изученными с точки зрения влияния на сердечно-сосудистые риски и представляющими интерес в плане функционирования при состояниях, сопряженных с клиникой МС, являются ангиопоэтин-подобные белки 3-го и 4-го типа. В настоящем обзоре основное внимание уделено рассмотрению вклада ангиопоэтин-подобных белков 3-го и 4-го типа в развитие каждого состояния из «созвездия аномалий», характеризующих МС. На основании проведенного анализа современных данных в информационной базе PubMed продемонстрирована ключевая роль данных гепатокинов в качестве модуляторов взаимодействия между печенью и жировой тканью. Детально рассмотрено их участие в гомеостазе липидов, глюкозы, сахарного диабета 2-го типа, гипертензии, неалкогольной жировой болезни печени и апноэ во сне, т. е. в максимальном спектре состояний, определяющих МС. Показано, что ангиопоэтин-подобные белки 3-го и 4-го типа могут действовать как независимые предикторы МС, демонстрируя потенциальную роль в качестве прогностических биомаркеров метаболических нарушений. Понимание особенностей функционирования белков ангиопоэтин-подобной системы может предложить новые как диагностические, так и терапевтические подходы к заболеваниям, сопровождающимся нарушением обмена веществ. Пристальное нацеливание на ангиопоэтин-подобные белки 3-го и 4-го типа и разработка инновационных терапевтических методов с участием блокаторов их действия способны в ближайшей перспективе оказать существенное влияние на эффективность лечения метаболических нарушений у людей.

Metabolic syndrome (MetS) is a major global public health problem. Abdominal obesity, arterial hypertension, disorders of carbohydrate metabolism and dyslipidemia are widely recognized and the most important components of MetS. The angiopoietin-like system, which includes eight types of angiopoietin-like proteins (ANGPTLs), is recognized as an important regulator of adipose tissue function. Angiopoietin-like proteins types 3 and 4 (ANGPTL3/4) are the most studied in terms of their influence on cardiovascular risks and are of interest in terms of their function in conditions associated with MetS. This review focuses on considering the role of ANGPTL3/4 in the development of each condition from the constellation of abnormalities that characterize MetS. The key role of ANGPTL3/4 as modulators of the interaction between the liver and adipose tissue is demonstrated based on the analysis performed on the current data in the PubMed information. Their involvement in lipid homeostasis, glucose, type 2 diabetes, hypertension, non-alcoholic fatty liver disease and sleep apnea, i.e. in the maximum spectrum of conditions determining MetS, has been considered in detail. It’s been proven that ANGPTL3/4 can act as indepen dent predictors of MetS, demonstrating a potential role as prognostic biomarkers of metabolic disorders. Understanding the peculiarities of ANGPTLs functioning can offer both new diagnostic and therapeutic approaches to diseases with MetS. Close targeting of ANGPTL3/4 and the development of innovative therapies involving blockers of their action have the potential to have a significant impact on the effectiveness of treatment of metabolic disorders in humans in future.

дислипидемияожирениеартериальная гипертензиянарушения углеводного обменабиомаркерыгепатокины

dyslipidemiaobesityarterial hypertensioncarbohydrate metabolism disordersbiomarkershepatokines

References1

Saklayen MG. The Global Epidemic of the Metabolic Syndrome. Curr Hypertens Rep. 2018;20(2):12. https://doi.org/10.1007/s11906-018-0812-z.

Mendrick DL, Diehl AM, Topor LS, Dietert RR, Will Y, La Merrill MA et al. Metabolic Syndrome and Associated Diseases: From the Bench to the Clinic. Toxicol Sci. 2018;162(1):36–42. https://doi.org/10.1093/toxsci/kfx233.

Алексеева НС. Влияние компонентов метаболического синдрома на качество жизни пациентов. Acta Biomedica Scientifica. 2014;(6):9–13. Режим доступа: https://www.actabiomedica.ru/jour/article/view/1826.

Alekseeva NS. Influence of components of metabolic syndrome on the patients’ life quality. Acta Biomedica Scientifica. 2014;(6):9–13. (In Russ.) Available at: https://www.actabiomedica.ru/jour/article/view/1826.

Кытикова ОЮ, Антонюк МВ, Кантур ТА, Новгородцева ТП, Денисенко ЮК. Распространенность и биомаркеры метаболического синдрома. Ожирение и метаболизм. 2021;18(3):302–312. https://doi.org/10.14341/omet12704.

Kytikova OYu, Antonyuk MV, Kantur TA, Novgorodtseva TP, Denisenko YuK. Prevalence and biomarkers in metabolic syndrome. Obesity and Metabolism. 2021;18(3):302–312. (In Russ.) https://doi.org/10.14341/omet12704.

Chen YQ, Pottanat TG, Siegel RW, Ehsani M, Qian YW, Zhen EY et al. Angiopoietin-like protein 8 differentially regulates ANGPTL3 and ANGPTL4 during postprandial partitioning of fatty acids. J Lipid Res. 2020;61(8):1203–1220. https://doi.org/10.1194/jlr.RA120000781.

Wang Y, McNutt MC, Banfi S, Levin MG, Holland WL, Gusarova V et al. Hepatic ANGPTL3 regulates adipose tissue energy homeostasis. Proc Natl Acad Sci U S A. 2015;112(37):11630–11635. https://doi.org/10.1073/pnas.1515374112.

Dijk W, Heine M, Vergnes L, Boon MR, Schaart G, Hesselink MK et al. ANGPTL4 mediates shuttling of lipid fuel to brown adipose tissue during sustained cold exposure. Elife. 2015;4:e08428. https://doi.org/10.7554/eLife.08428.

Bini S, D’Erasmo L, Di Costanzo A, Minicocci I, Pecce V, Arca M. The Interplay between Angiopoietin-Like Proteins and Adipose Tissue: Another Piece of the Relationship between Adiposopathy and Cardiometabolic Diseases? Int J Mol Sci. 2021;22(2):742. https://doi.org/10.3390/ijms22020742.

Fazio S, Minnier J, Shapiro MD, Tsimikas S, Tarugi P, Averna MR et al. Threshold Effects of Circulating Angiopoietin-Like 3 Levels on Plasma Lipoproteins. J Clin Endocrinol Metab. 2017;102(9):3340–3348. https://doi.org/10.1210/jc.2016-4043.

Mattijssen F, Kersten S. Regulation of triglyceride metabolism by Angiopoietin-like proteins. Biochim Biophys Acta. 2012;1821(5):782–789. https://doi.org/10.1016/j.bbalip.2011.10.010.

Yin W, Romeo S, Chang S, Grishin NV, Hobbs HH, Cohen JC. Genetic variation in ANGPTL4 provides insights into protein processing and function. J Biol Chem. 2009;284(19):13213–13222. https://doi.org/10.1074/jbc.M900553200.

Oteng AB, Ruppert PMM, Boutens L, Dijk W, van Dierendonck XAMH, Olivecrona G et al. Characterization of ANGPTL4 function in macrophages and adipocytes using Angptl4-knockout and Angptl4-hypomorphic mice. J Lipid Res. 2019;60(10):1741–1754. https://doi.org/10.1194/jlr.M094128.

Iqbal J, Al Qarni A, Hawwari A, Alghanem AF, Ahmed G. Metabolic Syndrome, Dyslipidemia and Regulation of Lipoprotein Metabolism. Curr Diabetes Rev. 2018;14(5):427–433. https://doi.org/10.2174/1573399813666170705161039.

Allan CM, Larsson M, Jung RS, Ploug M, Bensadoun A, Beigneux AP et al. Mobility of “HSPG-bound” LPL explains how LPL is able to reach GPIHBP1 on capillaries. J Lipid Res. 2017;58(1):216–225. https://doi.org/10.1194/jlr.M072520.

Beigneux AP, Allan CM, Sandoval NP, Cho GW, Heizer PJ, Jung RS et al. Lipoprotein lipase is active as a monomer. Proc Natl Acad Sci U S A. 2019;116(13):6319–6328. https://doi.org/10.1073/pnas.1900983116.

Kristensen KK, Midtgaard SR, Mysling S, Kovrov O, Hansen LB, Skar-Gislinge N et al. A disordered acidic domain in GPIHBP1 harboring a sulfated tyrosine regulates lipoprotein lipase. Proc Natl Acad Sci U S A. 2018;115(26):E6020–E6029. https://doi.org/10.1073/pnas.1806774115.

Li Y, He PP, Zhang DW, Zheng XL, Cayabyab FS, Yin WD, Tang CK. Lipoprotein lipase: from gene to atherosclerosis. Atherosclerosis. 2014;237(2):597–608. https://doi.org/10.1016/j.atherosclerosis.2014.10.016.

Sato K, Okajima F, Miyashita K, Imamura S, Kobayashi J, Stanhope KL et al. The majority of lipoprotein lipase in plasma is bound to remnant lipoproteins: A new definition of remnant lipoproteins. Clin Chim Acta. 2016;461:114–125. https://doi.org/10.1016/j.cca.2016.06.020.

Aryal B, Singh AK, Zhang X, Varela L, Rotllan N, Goedeke L et al. Absence of ANGPTL4 in adipose tissue improves glucose tolerance and attenuates atherogenesis. JCI Insight. 2018;3(6):e97918. https://doi.org/10.1172/jci.insight.97918.

Hassan M. ANGPLT3: A novel modulator of lipid metabolism. Glob Cardiol Sci Pract. 2017;(1):e201706. https://doi.org/10.21542/gcsp.2017.6.

Morelli MB, Chavez C, Santulli G. Angiopoietin-like proteins as therapeutic targets for cardiovascular disease: focus on lipid disorders. Expert Opin Ther Targets. 2020;24(1):79–88. https://doi.org/10.1080/14728222.2020.1707806.

Wang Y, Gusarova V, Banfi S, Gromada J, Cohen JC, Hobbs HH. Inactivation of ANGPTL3 reduces hepatic VLDL-triglyceride secretion. J Lipid Res. 2015;56(7):1296–1307. https://doi.org/10.1194/jlr.M054882.

Zhu WF, Wang CL, Liang L, Shen Z, Fu JF, Liu PN et al. Triglyceride-raising APOA5 genetic variants are associated with obesity and non-HDL-C in Chinese children and adolescents. Lipids Health Dis. 2014;13:93. https://doi.org/10.1186/1476-511X-13-93.

Tikka A, Jauhiainen M. The role of ANGPTL3 in controlling lipoprotein metabolism. Endocrine. 2016;52(2):187–193. https://doi.org/10.1007/s12020-015-0838-9.

Lian SH, Hsu BG, Wang JH, Chen MC. Positive correlation of serum angiopoietin-like protein 3 levels with metabolic syndrome in patients with coronary artery disease. Tzu Chi Med J. 2021;34(1):75–81. https://doi.org/10.4103/tcmj.tcmj_49_21.

Lang W, Frishman WH. Angiopoietin-Like 3 Protein Inhibition: A New Frontier in Lipid-Lowering Treatment. Cardiol Rev. 2019;27(4):211–217. https://doi.org/10.1097/CRD.0000000000000258.

Kovrov O, Kristensen KK, Larsson E, Ploug M, Olivecrona G. On the mechanism of angiopoietin-like protein 8 for control of lipoprotein lipase activity. J Lipid Res. 2019;60(4):783–793. https://doi.org/10.1194/jlr.M088807.

Dewey FE, Gusarova V, O’Dushlaine C, Gottesman O, Trejos J, Hunt C et al. Inactivating Variants in ANGPTL4 and Risk of Coronary Artery Disease. N Engl J Med. 2016;374(12):1123–1133. https://doi.org/10.1056/NEJMoa1510926.

Chi X, Britt EC, Shows HW, Hjelmaas AJ, Shetty SK, Cushing EM et al. ANGPTL8 promotes the ability of ANGPTL3 to bind and inhibit lipoprotein lipase. Mol Metab. 2017;6(10):1137–1149. https://doi.org/10.1016/j.molmet.2017.06.014.

Crewe C, An YA, Scherer PE. The ominous triad of adipose tissue dysfunction: inflammation, fibrosis, and impaired angiogenesis. J Clin Invest. 2017;127(1):74–82. https://doi.org/10.1172/JCI88883.

Dijk W, Kersten S. Regulation of lipid metabolism by angiopoietin-like proteins. Curr Opin Lipidol. 2016;27(3):249–256. https://doi.org/10.1097/MOL.0000000000000290.

Tikkanen E, Minicocci I, Hällfors J, Di Costanzo A, D’Erasmo L, Poggiogalle E et al. Metabolomic Signature of Angiopoietin-Like Protein 3 Deficiency in Fasting and Postprandial State. Arterioscler Thromb Vasc Biol. 2019;39(4):665–674. https://doi.org/10.1161/ATVBAHA.118.312021.

Schinzari F, Vizioli G, Campia U, Tesauro M, Cardillo C. Variable Changes of Circulating ANGPTL3 and ANGPTL4 in Different Obese Phenotypes: Relationship with Vasodilator Dysfunction. Biomedicines. 2021;9(8):1037. https://doi.org/10.3390/biomedicines9081037.

Abu-Farha M, Al-Khairi I, Cherian P, Chandy B, Sriraman D, Alhubail A et al. Increased ANGPTL3, 4 and ANGPTL8/betatrophin expression levels in obesity and T2D. Lipids Health Dis. 2016;15(1):181. https://doi.org/10.1186/s12944-016-0337-x.

Cinkajzlová A, Mráz M, Lacinová Z, Kloučková J, Kaválková P, Kratochvílová H et al. Angiopoietin-like protein 3 and 4 in obesity, type 2 diabetes mellitus, and malnutrition: the effect of weight reduction and realimentation. Nutr Diabetes. 2018;8(1):21. https://doi.org/10.1038/s41387-018-0032-2.

Sadeghabadi ZA, Nourbakhsh M, Alaee M, Nourbakhsh M, Ghorbanhosseini SS, Sharifi R, Razzaghy-Azar M. Angiopoietin-Like Proteins 2 and 3 in Children and Adolescents with Obesity and Their Relationship with Hypertension and Metabolic Syndrome. Int J Hypertens. 2021:6748515. https://doi.org/10.1155/2021/6748515.

Sadeghabadi ZA, Nourbakhsh M, Alaee M, Larijani B, Razzaghy-Azar M. Peroxisome proliferator-activated receptor gamma expression in peripheral blood mononuclear cells and angiopoietin-like protein 4 levels in obese children and adolescents. J Endocrinol Invest. 2018;41(2):241–247. https://doi.org/10.1007/s40618-017-0730-y.

Parhofer KG. Interaction between Glucose and Lipid Metabolism: More than Diabetic Dyslipidemia. Diabetes Metab J. 2015;39(5):353–362. https://doi.org/10.4093/dmj.2015.39.5.353.

Robciuc MR, Maranghi M, Lahikainen A, Rader D, Bensadoun A, Öörni K et al. Angptl3 deficiency is associated with increased insulin sensitivity, lipoprotein lipase activity, and decreased serum free fatty acids. Arterioscler Thromb Vasc Biol. 2013;33(7):1706–1713. https://doi.org/10.1161/ATVBAHA.113.301397.

Robciuc MR, Tahvanainen E, Jauhiainen M, Ehnholm C. Quantitation of serum angiopoietin-like proteins 3 and 4 in a Finnish population sample. J Lipid Res. 2010;51(4):824–831. https://doi.org/10.1194/jlr.M002618.

Nidhina Haridas PA, Soronen J, Sädevirta S, Mysore R, Quagliarini F, Pasternack A et al. Regulation of Angiopoietin-Like Proteins (ANGPTLs) 3 and 8 by Insulin. J Clin Endocrinol Metab. 2015;100(10):E1299–1307. https://doi.org/10.1210/jc.2015-1254.

Harada M, Yamakawa T, Kashiwagi R, Ohira A, Sugiyama M, Sugiura Y et al. Association between ANGPTL3, 4, and 8 and lipid and glucose metabolism markers in patients with diabetes. PLoS ONE. 2021;16(7):e0255147. https://doi.org/10.1371/journal.pone.0255147.

Zhao D, Yang LY, Wang XH, Yuan SS, Yu CG, Wang ZW et al. Different relationship between ANGPTL3 and HDL components in female non-diabetic subjects and type-2 diabetic patients. Cardiovasc Diabetol. 2016;15(1):132. https://doi.org/10.1186/s12933-016-0450-1.

Hoang Thi M, Dang Thanh C, Huynh Quang T. The Correlation Between Angiopoietin-Like 3 and Metabolic Markers of Some Lipid and Glucose in Type 2 Diabetes Mellitus Patients at the First Diagnosis. Diabetes Metab Syndr Obes. 2022;15:3329–3337. https://doi.org/10.2147/DMSO.S383234.

Chen MC, Hsu BG, Lee CJ, Yang CF, Wang JH. High serum adipocyte fatty acid binding protein level as a potential biomarker of aortic arterial stiffness in hypertensive patients with metabolic syndrome. Clin Chim Acta. 2017;473:166–172. https://doi.org/10.1016/j.cca.2017.08.030.

Janssen AWF, Katiraei S, Bartosinska B, Eberhard D, Willems van Dijk K, Kersten S. Loss of angiopoietin-like 4 (ANGPTL4) in mice with diet-induced obesity uncouples visceral obesity from glucose intolerance partly via the gut microbiota. Diabetologia. 2018;61(6):1447–1458. https://doi.org/10.1007/s00125-018-4583-5.

Barja-Fernandez S, Moreno-Navarrete JM, Folgueira C, Xifra G, Sabater M, Castelao C et al. Plasma ANGPTL-4 is Associated with Obesity and Glucose Tolerance: Cross-Sectional and Longitudinal Findings. Mol Nutr Food Res. 2018;62(10):e1800060. https://doi.org/10.1002/mnfr.201800060.

Tjeerdema N, Georgiadi A, Jonker JT, van Glabbeek M, Alizadeh Dehnavi R, Tamsma JT et al. Inflammation increases plasma angiopoietin-like protein 4 in patients with the metabolic syndrome and type 2 diabetes. BMJ Open Diabetes Res Care. 2014;2(1):e000034. https://doi.org/10.1136/bmjdrc-2014-000034.

Barchetta I, Chiappetta C, Ceccarelli V, Cimini FA, Bertoccini L, Gaggini M et al. Angiopoietin-Like Protein 4 Overexpression in Visceral Adipose Tissue from Obese Subjects with Impaired Glucose Metabolism and Relationship with Lipoprotein Lipase. Int J Mol Sci. 2020;21(19):7197. https://doi.org/10.3390/ijms21197197.

Chen MC, Hsu BG, Lee CJ, Wang JH. High-Serum Angiopoietin-Like Protein 3 Levels Associated with Cardiovascular Outcome in Patients with Coronary Artery Disease. Int J Hypertens. 2020:2980954. https://doi.org/10.1155/2020/2980954.

Hussain A, Sun C, Selvin E, Nambi V, Coresh J, Jia X et al. Triglyceride-rich lipoproteins, apolipoprotein C-III, angiopoietin-like protein 3, and cardiovascular events in older adults: Atherosclerosis Risk in Communities (ARIC) study. Eur J Prev Cardiol. 2022;29(2):e53–e64. https://doi.org/10.1093/eurjpc/zwaa152.

Abu-Farha M, Cherian P, Qaddoumi MG, AlKhairi I, Sriraman D, Alanbaei M, Abubaker J. Increased plasma and adipose tissue levels of ANGPTL8/ Betatrophin and ANGPTL4 in people with hypertension. Lipids Health Dis. 2018;17(1):35. https://doi.org/10.1186/s12944-018-0681-0.

Xu F, Shen L, Yang Y, Kong L, Zu W, Tian D et al. Association Between Plasma Levels of ANGPTL3, 4, 8 and the Most Common Additional Cardiovascular Risk Factors in Patients with Hypertension. Diabetes Metab Syndr Obes. 2023;16:1647–1655. https://doi.org/10.2147/DMSO.S411483.

Fortini F, Vieceli Dalla Sega F, Marracino L, Severi P, Rapezzi C, Rizzo P, Ferrari R. Well-Known and Novel Players in Endothelial Dysfunction: Updates on a Notch(ed) Landscape. Biomedicines. 2021;9(8):997. https://doi.org/10.3390/biomedicines9080997.

Ali F, Khan A, Muhammad SA, Hassan SSU. Quantitative Real-Time Analysis of Differentially Expressed Genes in Peripheral Blood Samples of Hypertension Patients. Genes (Basel). 2022;13(2):187. https://doi.org/10.3390/genes13020187.

Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol. 2020;73(1):202–209. https://doi.org/10.1016/j.jhep.2020.03.039.

Eslam M, Sanyal AJ, George J. MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease. Gastroenterology. 2020;158(7):1999–2014.e1. https://doi.org/10.1053/j.gastro.2019.11.312.

Ke Y, Liu S, Zhang Z, Hu J. Circulating angiopoietin-like proteins in metabolicassociated fatty liver disease: a systematic review and meta-analysis. Lipids Health Dis. 2021;20(1):55. https://doi.org/10.1186/s12944-021-01481-1.

Barchetta I, Cimini FA, Chiappetta C, Bertoccini L, Ceccarelli V, Capoccia D et al. Relationship between hepatic and systemic angiopoietin-like 3, hepatic Vitamin D receptor expression and NAFLD in obesity. Liver Int. 2020;40(9):2139–2147. https://doi.org/10.1111/liv.14554.

Hu X, Fan J, Ma Q, Han L, Cao Z, Xu C et al. A novel nanobody-heavy chain antibody against Angiopoietin-like protein 3 reduces plasma lipids and relieves nonalcoholic fatty liver disease. J Nanobiotechnology. 2022;20(1):237. https://doi.org/10.1186/s12951-022-01456-z.

Al-Terki A, Abu-Farha M, AlKhairi I, Cherian PT, Sriraman D, Shyamsundar A et al. Increased Level of Angiopoietin Like Proteins 4 and 8 in People With Sleep Apnea. Front Endocrinol (Lausanne). 2018;9:651. https://doi.org/10.3389/fendo.2018.00651.

Li J, Yang Y, Jiao X, Yu H, Du Y, Zhang M et al. The Clinical Role of AngiopoietinLike Protein 3 in Evaluating Coronary Artery Disease in Patients with Obstructive Sleep Apnea. Cardiovasc Drugs Ther. 2020;34(6):773–780. https://doi.org/10.1007/s10557-020-06991-1.

Lv Q, Jiao X, Yu H, Sun Q, Li F, Wang Y et al. ANGPTL3 and Cardiovascular Outcomes in Patients With Acute Coronary Syndrome and Obstructive Sleep Apnea. J Am Heart Assoc. 2022;11(18):e025955. https://doi.org/10.1161/JAHA.122.025955.

Aryal B, Price NL, Suarez Y, Fernández-Hernando C. ANGPTL4 in Metabolic and Cardiovascular Disease. Trends Mol Med. 2019;25(8):723–734. https://doi.org/10.1016/j.molmed.2019.05.010.

Pérez-Martínez P, Mikhailidis DP, Athyros VG, Bullo M, Couture P, Covas MI et al. Lifestyle recommendations for the prevention and management of metabolic syndrome: an international panel recommendation. Nutr Rev. 2017;75(5):307–326. https://doi.org/10.1093/nutrit/nux014.

The authors declare that there are no conflicts of interest present.